References
- McDonald JE, Padmanabhan N, Petrie MC, et al. Vasoconstrictor effect of the angiotensinconverting enzymeresistant, chymasespecific substrate [Pro(11)(D)Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of nonace production of angiotensin II in humans. Circulation 2001;104:1805–8
- Matsumoto T, Wada A, Tsutamoto T, et al. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003;107:2555–8
- Arakawa K, Urata H. Hypothesis regarding the pathophysiological role of alternative pathways of angiotensin II formation in atherosclerosis. Hypertension 2000;36:638–41
- Hill CE, Hirst GD, Silverberg GD, et al. Sympathetic innervation and excitability of arterioles originating from the rat middle cerebral artery. J Physiol 1986;371:305–16
- Boehm S, Kubista H. Fine tuning of sympathetic transmitter release via ionotropic and metabotropic presynaptic receptors. Pharmacol Rev 2002;54:43–99
- Pinheiro H, Moura D, binoTeixeira A, et al. A comparison of AT1 angiotensin II antagonists at pre and postjunctional angiotensin II receptors of the rat tail artery. Naunyn Schmiedebergs Arch Pharmacol 2002;366: 537–42
- Guimaraes S, Carneiro C, Brandao F, et al. A pharmacological differentiation between postjunctional (AT1A) and prejunctional (AT1B) angiotensin II receptors in the rabbit aorta. Naunyn Schmiedebergs Arch Pharmacol 2004;370:262–9
- Rupp H, Benkel M, Maisch B. Control of cardiomyocyte gene expression as drug target. Mol Cell Biochem 2000;212:135–42
- Ohlstein EH, Brooks DP, Feuerstein GZ, et al. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997;55:244–51
- Arosio E, De MS, Prior M, et al. Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress. J Hypertens 2005;23:1923–7
- Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022–31
- Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049–51
- Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218–26
- Staessen JA, Fagard R, Thijs L, et al. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (SystEur) Trial Investigators. Lancet 1997;350:757–64
- Rabbia F, Martini G, Cat Genova G, et al. Antihypertensive drugs and sympathetic nervous system. Clin Exp Hypertens 2001;23:101–11
- Pinheiro H, Moura D, AlbinoTeixeira A, et al. A comparison of AT1 angiotensin II antagonists at pre and postjunctional angiotensin II receptors of the rat tail artery. Naunyn Schmiedebergs Arch Pharmacol 2002;366: 537–42
- de la Sierra A, Munoz A, Arcos E, et al. Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension. Blood Press Suppl 2004;2:5–10